Disappointing result … a famous vaccine that may not defeat the mutated Corona!

While the world waits for good with the extension of the vaccination campaigns against Corona, a study linked to one of the famous vaccines has given disappointing results.

A recent study carried out in scientific laboratories and published in the “New England Journal of Medicine” revealed that the mutated strain of the Corona virus which appeared in South Africa reduced the effectiveness of the antibodies produced by the PfizerBioNTech vaccine by two thirds and this It’s not clear whether the second dose will be effective against the boom.

In detail, the researchers tested the modified virus on blood samples taken from people who received the vaccine and found a two-thirds decrease in the level of neutralizing antibodies compared to its effect on the most common version of the vaccine. virus prevalent in the American experiments.

Expressive Corona Vaccine

Since there is no specific standard yet to determine the level of antibodies needed to protect against the virus, it is currently unclear whether this two-thirds decrease will make the vaccine effective against the mutated virus that started to spread around the world.

Postpone vaccination

In addition, two researchers urged governments to postpone vaccination with the second dose of Pfizer’s Covid-19 vaccine, which they say has 92.6% effectiveness after the first dose.

Researchers Danuta Skoronsky and Gaston de Serce said they came to this conclusion, based on documents provided by Pfizer to the United States Food and Drug Administration.

They also mentioned in a letter published in the New England Journal of Medicine that these results are similar to those related to the vaccine produced by Moderna and that its effectiveness rate after the first dose was 92.1%.

Expressive

without interest

Additionally, they warned that there might be uncertainty about how long a dose will protect, but vaccinating with the second dose one month after the first does not provide much short-term benefit. And they said: vaccine shortage, postponing the second dose is a matter of national security. If ignored, it will certainly lead to thousands of hospitalizations and deaths from Covid-19 this winter in the United States. “

In contrast, and in response to those findings, Pfizer said a change in the vaccination system with two doses of the vaccine has yet to be evaluated, adding that this decision is left to health authorities.